Innovus Pharmaceuticals (INNVD) vs. The Competition Head to Head Survey

Innovus Pharmaceuticals (OTCMKTS: INNVD) is one of 555 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Innovus Pharmaceuticals to similar companies based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.

Volatility and Risk

Innovus Pharmaceuticals has a beta of 2.89, indicating that its stock price is 189% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals’ rivals have a beta of 1.33, indicating that their average stock price is 33% more volatile than the S&P 500.

Profitability

This table compares Innovus Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innovus Pharmaceuticals -34.51% -682.54% -78.57%
Innovus Pharmaceuticals Competitors -1,563.74% -832.39% -27.72%

Earnings & Valuation

This table compares Innovus Pharmaceuticals and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Innovus Pharmaceuticals $23.99 million -$8.28 million -0.50
Innovus Pharmaceuticals Competitors $2.14 billion $224.95 million -3.82

Innovus Pharmaceuticals’ rivals have higher revenue and earnings than Innovus Pharmaceuticals. Innovus Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Innovus Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovus Pharmaceuticals 0 0 0 0 N/A
Innovus Pharmaceuticals Competitors 4733 13416 28189 1021 2.54

As a group, “Pharmaceutical preparations” companies have a potential upside of 59.06%. Given Innovus Pharmaceuticals’ rivals higher possible upside, analysts clearly believe Innovus Pharmaceuticals has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 16.4% of Innovus Pharmaceuticals shares are owned by company insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.